Last: | $0.8802 |
---|---|
Change Percent: | -5.56% |
Open: | $0.94 |
Close: | $0.932 |
High: | $0.94 |
Low: | $0.84 |
Volume: | 420,233 |
Last Trade Date Time: | 07/17/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.8802 | $0.94 | $0.932 | $0.94 | $0.84 | 420,233 | 07-17-2024 |
$0.932 | $0.9589 | $0.932 | $0.975 | $0.9205 | 280,864 | 07-16-2024 |
$0.93 | $0.9617 | $0.93 | $1.0002 | $0.902 | 183,771 | 07-15-2024 |
$0.9402 | $0.9585 | $0.9402 | $1.0014 | $0.9338 | 309,663 | 07-12-2024 |
$0.9483 | $0.8739 | $0.9483 | $0.9568 | $0.85 | 494,451 | 07-11-2024 |
$0.8862 | $0.9771 | $0.8862 | $0.9798 | $0.8671 | 456,536 | 07-10-2024 |
$0.93 | $0.97 | $0.93 | $0.98 | $0.93 | 328,528 | 07-09-2024 |
$0.9769 | $0.98 | $0.9769 | $1.02 | $0.93 | 543,544 | 07-08-2024 |
$0.96 | $1 | $0.96 | $1.07 | $0.9595 | 258,168 | 07-05-2024 |
$0.98 | $1.08 | $0.98 | $1.0867 | $0.972 | 278,275 | 07-04-2024 |
$0.98 | $1.08 | $0.98 | $1.0867 | $0.972 | 278,275 | 07-03-2024 |
$1.08 | $1.04 | $1.08 | $1.13 | $1.02 | 566,833 | 07-02-2024 |
$1.02 | $1.26 | $1.02 | $1.29 | $0.9371 | 1,531,404 | 07-01-2024 |
$1.24 | $1.41 | $1.24 | $1.4385 | $1.24 | 4,053,260 | 06-28-2024 |
$1.4 | $1.36 | $1.4 | $1.49 | $1.34 | 267,043 | 06-27-2024 |
$1.38 | $1.47 | $1.38 | $1.58 | $1.38 | 313,689 | 06-26-2024 |
$1.445 | $1.46 | $1.445 | $1.47 | $1.37 | 325,907 | 06-25-2024 |
$1.47 | $1.42 | $1.47 | $1.49 | $1.365 | 298,670 | 06-24-2024 |
$1.35 | $1.3 | $1.35 | $1.37 | $1.26 | 331,762 | 06-21-2024 |
$1.3 | $1.35 | $1.3 | $1.43 | $1.29 | 213,610 | 06-20-2024 |
News, Short Squeeze, Breakout and More Instantly...
Overall response rate (ORR) of 46% and 12-month overall survival (OS) of 96% in first line (1L) recurrent/metastatic (R/M) HPV+ head and neck squamous cell carcinoma (HNSCC) treated with CUE-101 and KEYTRUDA ® (pembrolizumab) Median overall survival (mOS) of 20.8 months in second...
BOSTON, June 03, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, today announced that it will participate in two investor confe...
BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells, today provided a business and financial update for the first qua...